Publications by authors named "Li-Xuan Sim"
Cancer Discov
February 2024
Article Synopsis
- * The PlasmaMATCH study found that 4% of patients developed new ESR1 F404 mutations that can disrupt fulvestrant binding, leading to reduced treatment sensitivity, with various combinations of mutations affecting resistance levels.
- * Identifying these F404 mutations provides insights into drug-specific resistance mechanisms to fulvestrant and highlights the potential for new oral estrogen receptor degraders to target complex mutant profiles in ongoing clinical development.
View Article and Find Full Text PDF